AMRI Files New Patent Infringement Lawsuits against Dr. Reddy's Laboratories (RDY) and Sandoz
More News related to AMRI
- Albany Molecular Research (AMRI) Posts Q3 Loss of $0.02, Tops by 2c; Guides
- AMRI Announces Third Quarter 2009 Results
- Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report
- Third Compound from AMRI Bristol-Myers Squibb Collaboration Selected for Preclinical Development
- AMRI to Present at the Oppenheimer 20th Annual Healthcare Conference
More News related to RDY
- Dr. Reddy's Q2 FY10 Results
- Dr. Reddy's to release Q2 FY10 results on Oct 23, 2009; Earnings call slated for Oct 23, 6.00 PM IST / 8.30 AM EST
- Morgan Stanley Upgrades Dr. Reddy's Labs (RDY) to Overweight
- AMRI Files New Patent Infringement Lawsuits against Dr. Reddy's Laboratories (RDY) and Sandoz
- Pozen (POZN) Receives Notice from Dr. Reddy's Labs (RDY) Indicating Dr. Reddy's has Filed an ANDA to Market a Generic Version of Treximet
More News related to Corporate News
- Human Genome Sciences (HGSI) Submits BLA to U.S. FDA for Hep C Treatment ZALBIN
- Incyte (INCY) In License Agreement With Novartis, Worth Up to $1 Billion
- Gen-Probe (GPRO) Gets U.S. FDA Clearance for Marketing Prodesse's ProParaflu+ Assay
- Nanosphere (NSPH) Receives 510(k) from U.S. FDA to Update RVNATSP to Include Flu Cultured Clinical Isolates with H1N1 Virus
AMRI (NASDAQ: AMRI) announced that it has filed two new patent infringement lawsuits in U.S. District Court in New Jersey against Dr. Reddy's Laboratories, Ltd., Dr. Reddy's Laboratories (NYSE: RDY) and Sandoz, Inc. for infringement of AMRI's U.S. Patent Number 7,390,906. The recently issued patent relates to the manufacturing process for the active ingredient in sanofi-aventis's Allegra(R) and Allegra(R)D drug products.
This legal action relates to generic versions of sanofi-aventis's Allegra(R) and Allegra(R)D drug products for which the defendants are seeking or have obtained marketing approval from the FDA and which the defendants have marketed in the United States.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
